{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?page=17&sponsor=Novartis+Pharmaceuticals",
    "query": {
      "sponsor": "Novartis Pharmaceuticals",
      "page": 17
    },
    "page_size": 10
  },
  "pagination": {
    "page": 17,
    "page_size": 10,
    "total_count": 1758,
    "total_pages": 176,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=18&sponsor=Novartis+Pharmaceuticals&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=16&sponsor=Novartis+Pharmaceuticals&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-20T13:51:57.947Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02116803",
      "title": "An Open Label Multi-center Extension Study to Evaluate Long-term Safety/ Tolerability of Dovitinib in Patients With Solid Tumors Who Continue to Receive Treatment With Dovitinib (TKI258) in Novartis-sponsored Single Agent Dovitinib Studies Which Fulfilled the Requirements for the Primary Objective",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Solid Tumors"
      ],
      "interventions": [
        {
          "name": "dovitinib",
          "type": "DRUG"
        },
        {
          "name": "fulvestrant",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2014-05-28",
      "completion_date": "2016-11-28",
      "has_results": true,
      "last_update_posted_date": "2018-03-01",
      "last_synced_at": "2026-10-20T13:51:57.947Z",
      "location_count": 2,
      "location_summary": "Las Vegas, Nevada • The Bronx, New York",
      "locations": [
        {
          "city": "Las Vegas",
          "state": "Nevada"
        },
        {
          "city": "The Bronx",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02116803"
    },
    {
      "nct_id": "NCT00303251",
      "title": "Safety of TKI258 in Advanced/Metastatic Melanoma Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "TKI258",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 47,
      "start_date": "2006-04",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2021-03-11",
      "last_synced_at": "2026-10-20T13:51:57.947Z",
      "location_count": 3,
      "location_summary": "Louisville, Kentucky • Pittsburgh, Pennsylvania • Houston, Texas",
      "locations": [
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00303251"
    },
    {
      "nct_id": "NCT05344482",
      "title": "Evaluation of the Effectiveness of Secukinumab in Patients With Moderate to Severe Plaque Psoriasis",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Plaque Psoriasis"
      ],
      "interventions": [
        {
          "name": "Secukinumab",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 277,
      "start_date": "2020-07-09",
      "completion_date": "2021-08-31",
      "has_results": false,
      "last_update_posted_date": "2022-07-01",
      "last_synced_at": "2026-10-20T13:51:57.947Z",
      "location_count": 1,
      "location_summary": "East Hanover, New Jersey",
      "locations": [
        {
          "city": "East Hanover",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05344482"
    },
    {
      "nct_id": "NCT03506802",
      "title": "TCR Genetically Engineered PBMC and PBSC After Melphalan Conditioning Regimen in Treating Participants With Relapsed and Refractory Multiple Myeloma",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HLA-A*0201 Positive Cells Present",
        "NY-ESO-1 Positive Tumor Cells Present",
        "Recurrent Plasma Cell Myeloma",
        "Refractory Plasma Cell Myeloma"
      ],
      "interventions": [
        {
          "name": "18F-FHBG",
          "type": "RADIATION"
        },
        {
          "name": "Aldesleukin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cellular Therapy",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Lenalidomide",
          "type": "DRUG"
        },
        {
          "name": "Leukapheresis",
          "type": "PROCEDURE"
        },
        {
          "name": "Melphalan",
          "type": "DRUG"
        },
        {
          "name": "Plerixafor",
          "type": "DRUG"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "BIOLOGICAL",
        "PROCEDURE",
        "OTHER",
        "DRUG"
      ],
      "sponsor": "Jonsson Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2018-07-10",
      "completion_date": "2019-06-25",
      "has_results": false,
      "last_update_posted_date": "2020-07-24",
      "last_synced_at": "2026-10-20T13:51:57.947Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03506802"
    },
    {
      "nct_id": "NCT04699188",
      "title": "Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "KRAS G12C Mutant Solid Tumors",
        "Carcinoma, Non-Small-Cell Lung",
        "Carcinoma, Colorectal",
        "Cancer of Lung",
        "Cancer of the Lung",
        "Lung Cancer",
        "Neoplasms, Lung",
        "Neoplasms, Pulmonary",
        "Pulmonary Cancer",
        "Pulmonary Neoplasms"
      ],
      "interventions": [
        {
          "name": "JDQ443",
          "type": "DRUG"
        },
        {
          "name": "TNO155",
          "type": "DRUG"
        },
        {
          "name": "tislelizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 344,
      "start_date": "2021-02-24",
      "completion_date": "2027-01-25",
      "has_results": false,
      "last_update_posted_date": "2026-10-19",
      "last_synced_at": "2026-10-20T13:51:57.947Z",
      "location_count": 5,
      "location_summary": "Atlanta, Georgia • Boston, Massachusetts • Pittsburgh, Pennsylvania + 1 more",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04699188"
    },
    {
      "nct_id": "NCT02936102",
      "title": "A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumors",
        "Triple Negative Breast Cancer",
        "Chordoma and Alveolar Soft Part Sarcoma"
      ],
      "interventions": [
        {
          "name": "FAZ053",
          "type": "DRUG"
        },
        {
          "name": "PDR001",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 154,
      "start_date": "2016-10-20",
      "completion_date": "2024-11-22",
      "has_results": false,
      "last_update_posted_date": "2025-11-14",
      "last_synced_at": "2026-10-20T13:51:57.947Z",
      "location_count": 2,
      "location_summary": "New York, New York • Houston, Texas",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02936102"
    },
    {
      "nct_id": "NCT00732888",
      "title": "Effect of Calcium on Tasigna Pharmacokinetics (PK) in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Nilotinib Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "calcium carbonate",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Jan Beumer",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 14,
      "start_date": "2008-11",
      "completion_date": "2011-09",
      "has_results": false,
      "last_update_posted_date": "2013-12-18",
      "last_synced_at": "2026-10-20T13:51:57.947Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00732888"
    },
    {
      "nct_id": "NCT03930641",
      "title": "Study of the Safety of Brolucizumab 6 mg in Prefilled Syringe in Patients With Neovascular Age Related Macular Degeneration",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Neovascular Age Related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "RTH258",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 34,
      "start_date": "2019-05-23",
      "completion_date": "2019-07-02",
      "has_results": true,
      "last_update_posted_date": "2021-01-05",
      "last_synced_at": "2026-10-20T13:51:57.947Z",
      "location_count": 3,
      "location_summary": "Altamonte Springs, Florida • Pensacola, Florida • Richmond, Virginia",
      "locations": [
        {
          "city": "Altamonte Springs",
          "state": "Florida"
        },
        {
          "city": "Pensacola",
          "state": "Florida"
        },
        {
          "city": "Richmond",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03930641"
    },
    {
      "nct_id": "NCT02748863",
      "title": "Study of Secukinumab With 2 mL Pre-filled Syringes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Psoriasis"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Secukinumab 2 mL form",
          "type": "DRUG"
        },
        {
          "name": "Secukinumab 1 mL form",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 214,
      "start_date": "2016-12-12",
      "completion_date": "2018-06-08",
      "has_results": true,
      "last_update_posted_date": "2019-07-15",
      "last_synced_at": "2026-10-20T13:51:57.947Z",
      "location_count": 15,
      "location_summary": "Phoenix, Arizona • Fountain Valley, California • Fremont, California + 11 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Fremont",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Marietta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02748863"
    },
    {
      "nct_id": "NCT05109728",
      "title": "A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent.",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Glioblastoma"
      ],
      "interventions": [
        {
          "name": "[177Lu]Lu-DOTA-TATE",
          "type": "DRUG"
        },
        {
          "name": "[68Ga]Ga-DOTA-TATE",
          "type": "DRUG"
        },
        {
          "name": "Temozolomide",
          "type": "OTHER"
        },
        {
          "name": "Radiotherapy",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 63,
      "start_date": "2022-05-10",
      "completion_date": "2027-05-24",
      "has_results": false,
      "last_update_posted_date": "2026-09-22",
      "last_synced_at": "2026-10-20T13:51:57.947Z",
      "location_count": 4,
      "location_summary": "New York, New York • Pittsburgh, Pennsylvania • Houston, Texas + 1 more",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05109728"
    }
  ]
}